- Home
- ARGX vs IDXX Comparison
ARGX vs IDXX Comparison
Compare ARGX & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- IDXX
- Stock Information
- Founded
- ARGX 2008
- IDXX 1983
- Country
- ARGX Netherlands
- IDXX United States
- Employees
- ARGX N/A
- IDXX N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- IDXX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ARGX Health Care
- IDXX Health Care
- Exchange
- ARGX Nasdaq
- IDXX Nasdaq
- Market Cap
- ARGX 40.4B
- IDXX 34.1B
- IPO Year
- ARGX 2017
- IDXX 1991
- Fundamental
- Price
- ARGX $596.20
- IDXX $411.49
- Analyst Decision
- ARGX Strong Buy
- IDXX Buy
- Analyst Count
- ARGX 20
- IDXX 8
- Target Price
- ARGX $699.56
- IDXX $523.75
- AVG Volume (30 Days)
- ARGX 465.0K
- IDXX 1.0M
- Earning Date
- ARGX 05-08-2025
- IDXX 05-01-2025
- Dividend Yield
- ARGX N/A
- IDXX N/A
- EPS Growth
- ARGX N/A
- IDXX 6.06
- EPS
- ARGX 12.78
- IDXX 10.67
- Revenue
- ARGX $2,248,205,000.00
- IDXX $3,897,504,000.00
- Revenue This Year
- ARGX $57.86
- IDXX $7.74
- Revenue Next Year
- ARGX $31.90
- IDXX $7.74
- P/E Ratio
- ARGX $43.64
- IDXX $38.57
- Revenue Growth
- ARGX 77.22
- IDXX 6.46
- 52 Week Low
- ARGX $352.77
- IDXX $356.14
- 52 Week High
- ARGX $678.21
- IDXX $548.88
- Technical
- Relative Strength Index (RSI)
- ARGX 51.80
- IDXX 50.94
- Support Level
- ARGX $583.00
- IDXX $398.75
- Resistance Level
- ARGX $610.06
- IDXX $398.73
- Average True Range (ATR)
- ARGX 24.42
- IDXX 17.58
- MACD
- ARGX 4.74
- IDXX 2.10
- Stochastic Oscillator
- ARGX 84.66
- IDXX 77.88
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About IDXX IDEXX Laboratories Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.